1832 Asset Management’s Kite Pharma, Inc. KITE Stock Holding History

1832 Asset Management’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-301,000	Closed	-$30.5M	–	787
2017 Q2	$30.5M	Sell	301,000 -49,400	-14%	-$4.03M	0.14%	151
2017 Q1	$26.9M	Buy	+350,400	New	+$21.7M	0.1%	173
2016 Q3	–	Sell	-66,600	Closed	-$3.28M	–	786
2016 Q2	$3.28M	Buy	+66,600	New	+$3.27M	0.01%	331

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

1832 Asset Management's KITE Position: Q3 2017 in Review

1832 Asset Management sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 301,000 shares — an estimated $30.5M sold.

1832 Asset Management first reported a position in KITE in Q2 2016 and held it in 3 quarters. The position peaked at $30.5M in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

1832 Asset Management reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
1832 Asset Management sold 301,000 Kite Pharma, Inc. shares in Q3 2017, an estimated $30.5M.
1832 Asset Management first reported a position in Kite Pharma, Inc. in Q2 2016 and held it in 3 quarters.
1832 Asset Management's Kite Pharma, Inc. position peaked at $30.5M in Q2 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on 1832 Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.